{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:06:25Z","timestamp":1757617585493,"version":"3.44.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Health Sciences"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Abdom Radiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Aim<\/jats:title>\n            <jats:p>To evaluate the predictive value of multiphasic magnetic resonance imaging (MRI) in identifying liver tumor perfusion characteristics and to compare it with hepatic artery perfusion scintigraphy findings in patients considered for selective internal radiation therapy (SIRT) with yttrium-90 (Y-90).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This study included 93 patients diagnosed with primary or secondary liver cancer between May 2021 and February 2024, comprising 47 patients (27\u00a0M\/20F) deemed unsuitable for SIRT and 46 patients (26\u00a0M\/20F) eligible for SIRT. The relationship between multiphasic MRI and scintigraphy findings in determining perfusion of tumors was analyzed. Predictive performance was evaluated with receiver operating characteristic (ROC) analysis, and the optimal cut-off values were determined using the Youden index.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The SIRT unsuitable group had a lower frequency of intratumoral arterial phase hyperenhancement(APHE) (40.43% vs. 69.57%, <jats:italic>p<\/jats:italic>\u2009=\u20090.042), presence of hyperintensity on T2 sequence (72.34% vs. 95.65%, <jats:italic>p<\/jats:italic>\u2009=\u20090.026), lower lesion intensity in the portal phase (<jats:italic>p<\/jats:italic>\u2009=\u20090.033), and a lower lesion-to-liver intensity ratio in the portal phase (\u2264\u20090.97, <jats:italic>p<\/jats:italic>\u2009=\u20090.011). The absence of intratumoral APHE [<jats:italic>p<\/jats:italic>\u2009=\u20090.049, AUC (95% CI)\u2009=\u20090.646 (0.508\u20130.783)] and a lesion-to-liver intensity ratio in the portal phase with a cut-off value of \u2264\u20090.97 [<jats:italic>p<\/jats:italic>\u2009=\u20090.011, AUC (95% CI)\u2009=\u20090.689 (0.564\u20130.815)] were significant predictors of SIRT unsuitability.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Both the absence of intratumoral APHE and a lower lesion-to-liver intensity ratio in the portal phase were significant predictors of SIRT unsuitability.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Graphical Abstract<\/jats:title>\n          <\/jats:sec>","DOI":"10.1007\/s00261-025-04875-2","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T05:05:13Z","timestamp":1742187913000},"page":"4212-4223","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Usefulness of multiphasic MRI in assessing suitability for SIRT in treatment of liver malignancies"],"prefix":"10.1007","volume":"50","author":[{"given":"Cagri","family":"Erdim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elife","family":"Akgun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tevfik","family":"Guzelbey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gulsah","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet Hamza","family":"Turkcanoglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Dablan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Burcu","family":"Esen Akkas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ozgur","family":"Kilickesmez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,17]]},"reference":[{"key":"4875_CR1","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1200\/JCO.2008.20.7753","volume":"27","author":"SF Altekruse","year":"2009","unstructured":"Altekruse SF, McGlynn KA, Reichman ME (2009) Hepatocellular Carcinoma Incidence, Mortality, and Survival Trends in the United States From 1975 to 2005. Journal of Clinical Oncology 27:1485\u20131491","journal-title":"Journal of Clinical Oncology"},{"key":"4875_CR2","first-page":"217","volume":"11","author":"D Li","year":"2014","unstructured":"Li D, Kang J, Golas BJ, Yeung VW, Madoff DC (2014) Minimally invasive local therapies for liver cancer. Cancer Biol Med 11:217\u201336","journal-title":"Cancer Biol Med"},{"key":"4875_CR3","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.crad.2017.01.013","volume":"72","author":"L Crocetti","year":"2017","unstructured":"Crocetti L, Bargellini I, Cioni R (2017) Loco-regional treatment of HCC: current status. Clin Radiol 72:626\u2013635","journal-title":"Clin Radiol"},{"key":"4875_CR4","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.21037\/atm-20-2658","volume":"8","author":"M Masthoff","year":"2020","unstructured":"Masthoff M, Schindler P, Harders F, et al (2020) Repeated radioembolization in advanced liver cancer. Ann Transl Med 8:1055\u20131055","journal-title":"Ann Transl Med"},{"key":"4875_CR5","first-page":"e617","volume":"17","author":"P Gibbs","year":"2018","unstructured":"Gibbs P, Heinemann V, Sharma NK, et al (2018) Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies. Clin Colorectal Cancer 17:e617\u2013e629","journal-title":"Clin Colorectal Cancer"},{"key":"4875_CR6","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s00270-011-0142-x","volume":"35","author":"R-T Hoffmann","year":"2012","unstructured":"Hoffmann R-T, Paprottka PM, Sch\u00f6n A, et al (2012) Transarterial Hepatic Yttrium-90 Radioembolization in Patients with Unresectable Intrahepatic Cholangiocarcinoma: Factors Associated with Prolonged Survival. Cardiovasc Intervent Radiol 35:105\u2013116","journal-title":"Cardiovasc Intervent Radiol"},{"key":"4875_CR7","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1007\/s00270-017-1739-5","volume":"40","author":"EG Klompenhouwer","year":"2017","unstructured":"Klompenhouwer EG, Dresen RC, Verslype C, Laenen A, De Hertogh G, Deroose CM, Bonne L, Vandevaveye V, Maleux G (2017) Safety and Efficacy of Transarterial Radioembolisation in Patients with Intermediate or Advanced Stage Hepatocellular Carcinoma Refractory to Chemoembolisation. Cardiovasc Intervent Radiol 40:1882\u20131890","journal-title":"Cardiovasc Intervent Radiol"},{"key":"4875_CR8","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1002\/hep.29691","volume":"68","author":"R Salem","year":"2018","unstructured":"Salem R, Gabr A, Riaz A, et al (2018) Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15\u2010year experience. Hepatology 68:1429\u20131440","journal-title":"Hepatology"},{"key":"4875_CR9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40658-018-0221-z","volume":"5","author":"R Bastiaannet","year":"2018","unstructured":"Bastiaannet R, Kappadath SC, Kunnen B, Braat AJAT, Lam MGEH, de Jong HWAM (2018) The physics of radioembolization. EJNMMI Phys 5:22","journal-title":"EJNMMI Phys"},{"key":"4875_CR10","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13550-021-00837-z","volume":"11","author":"MF Georgiou","year":"2021","unstructured":"Georgiou MF, Kuker RA, Studenski MT, Ahlman PP, Witte M, Portelance L (2021) Lung shunt fraction calculation using 99mTc-MAA SPECT\/CT imaging for 90Y microsphere selective internal radiation therapy of liver tumors. EJNMMI Res 11:96","journal-title":"EJNMMI Res"},{"key":"4875_CR11","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s00535-009-0174-z","volume":"45","author":"Y Ni","year":"2010","unstructured":"Ni Y, Chen F, Wang H, Feng Y, Li J, Jiang Y (2010) Proper definitions of MRI contrast enhancement in liver tumors. J Gastroenterol 45:349\u2013350","journal-title":"J Gastroenterol"},{"key":"4875_CR12","doi-asserted-by":"publisher","first-page":"W44","DOI":"10.2214\/AJR.10.5845","volume":"197","author":"YJ Suh","year":"2011","unstructured":"Suh YJ, Kim M-J, Choi J-Y, Park YN, Park M-S, Kim KW (2011) Differentiation of Hepatic Hyperintense Lesions Seen on Gadoxetic Acid\u2013Enhanced Hepatobiliary Phase MRI. American Journal of Roentgenology 197:W44\u2013W52","journal-title":"American Journal of Roentgenology"},{"key":"4875_CR13","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.2214\/AJR.08.1946","volume":"193","author":"BB Frericks","year":"2009","unstructured":"Frericks BB, Loddenkemper C, Huppertz A, Valdeig S, Stroux A, Seja M, Wolf K-J, Albrecht T (2009) Qualitative and Quantitative Evaluation of Hepatocellular Carcinoma and Cirrhotic Liver Enhancement Using Gd-EOB-DTPA. American Journal of Roentgenology 193:1053\u20131060","journal-title":"American Journal of Roentgenology"},{"key":"4875_CR14","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.2967\/jnumed.112.117614","volume":"54","author":"M Wondergem","year":"2013","unstructured":"Wondergem M, Smits MLJ, Elschot M, de Jong HWAM, Verkooijen HM, van den Bosch MAAJ, Nijsen JFW, Lam MGEH (2013) 99m Tc-Macroaggregated Albumin Poorly Predicts the Intrahepatic Distribution of 90 Y Resin Microspheres in Hepatic Radioembolization. Journal of Nuclear Medicine 54:1294\u20131301","journal-title":"Journal of Nuclear Medicine"},{"key":"4875_CR15","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1186\/1471-2407-14-897","volume":"14","author":"P Gibbs","year":"2014","unstructured":"Gibbs P, Gebski V, Van Buskirk M, Thurston K, Cade DN, Van Hazel GA (2014) Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX study. BMC Cancer 14:897","journal-title":"BMC Cancer"},{"key":"4875_CR16","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1186\/1471-2407-14-497","volume":"14","author":"SJ Dutton","year":"2014","unstructured":"Dutton SJ, Kenealy N, Love SB, Wasan HS, Sharma RA (2014) FOXFIRE protocol: an open-label, randomised, phase III trial of 5-fluorouracil, oxaliplatin and folinic acid (OxMdG) with or without interventional Selective Internal Radiation Therapy (SIRT) as first-line treatment for patients with unresectable liver-only or liver-dominant metastatic colorectal cancer. BMC Cancer 14:497","journal-title":"BMC Cancer"},{"key":"4875_CR17","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1200\/JCO.2015.66.1181","volume":"34","author":"GA van Hazel","year":"2016","unstructured":"van Hazel GA, Heinemann V, Sharma NK, et al (2016) SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology 34:1723\u20131731","journal-title":"Journal of Clinical Oncology"},{"key":"4875_CR18","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/S1470-2045(17)30457-6","volume":"18","author":"HS Wasan","year":"2017","unstructured":"Wasan HS, Gibbs P, Sharma NK, et al (2017) First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. Lancet Oncol 18:1159\u20131171","journal-title":"Lancet Oncol"},{"key":"4875_CR19","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1016\/S1470-2045(17)30683-6","volume":"18","author":"V Vilgrain","year":"2017","unstructured":"Vilgrain V, Pereira H, Assenat E, et al (2017) Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol 18:1624\u20131636","journal-title":"Lancet Oncol"},{"key":"4875_CR20","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/COC.0b013e3181f47923","volume":"35","author":"D Coldwell","year":"2012","unstructured":"Coldwell D, Sangro B, Salem R, Wasan H, Kennedy A (2012) Radioembolization in the Treatment of Unresectable Liver Tumors. Am J Clin Oncol 35:167\u2013177","journal-title":"Am J Clin Oncol"},{"key":"4875_CR21","doi-asserted-by":"publisher","first-page":"4824","DOI":"10.1118\/1.3608909","volume":"38","author":"WA Dezarn","year":"2011","unstructured":"Dezarn WA, Cessna JT, DeWerd LA, et al (2011) Recommendations of the American Association of Physicists in Medicine on dosimetry, imaging, and quality assurance procedures for 90 Y microsphere brachytherapy in the treatment of hepatic malignancies. Med Phys 38:4824\u20134845","journal-title":"Med Phys"},{"key":"4875_CR22","doi-asserted-by":"publisher","DOI":"10.4172\/2155-9619.1000122","author":"M Jiang","year":"2012","unstructured":"Jiang M, Fischman A, Nowakowski FS (2012) Segmental Perfusion Differences on Paired Tc-99m Macroaggregated Albumin (MAA) Hepatic Perfusion Imaging and Yttrium-90 (Y-90) Bremsstrahlung Imaging Studies in SIR-Sphere Radioembolization: Associations with Angiography. J Nucl Med Radiat Ther. https:\/\/doi.org\/10.4172\/2155-9619.1000122","journal-title":"J Nucl Med Radiat Ther"},{"key":"4875_CR23","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1007\/s00259-020-04976-8","volume":"48","author":"A Gabr","year":"2021","unstructured":"Gabr A, Riaz A, Johnson GE, Kim E, Padia S, Lewandowski RJ, Salem R (2021) Correlation of Y90-absorbed radiation dose to pathological necrosis in hepatocellular carcinoma: confirmatory multicenter analysis in 45 explants. Eur J Nucl Med Mol Imaging 48:580\u2013583","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4875_CR24","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1007\/s00270-022-03215-x","volume":"45","author":"E Garin","year":"2022","unstructured":"Garin E, Guiu B, Edeline J, Rolland Y, Palard X (2022) Trans-arterial Radioembolization Dosimetry in 2022. Cardiovasc Intervent Radiol 45:1608\u20131621","journal-title":"Cardiovasc Intervent Radiol"},{"key":"4875_CR25","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.jvir.2024.01.031","volume":"35","author":"Q Yu","year":"2024","unstructured":"Yu Q, Neale M, Ungchusri E, Rothenberger NJ, Liao C, Patel M, Pillai A, Navuluri R, Ahmed O, Ha T Van (2024) Tumor Size and Watershed Area Correlate with Incomplete Treatment and Tumor Progression after Selective Radioembolization for Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology 35:712\u2013721.e3","journal-title":"Journal of Vascular and Interventional Radiology"},{"key":"4875_CR26","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1148\/radiol.2353040332","volume":"235","author":"S Shankar","year":"2005","unstructured":"Shankar S, vanSonnenberg E, Desai J, DiPiro PJ, Van Den Abbeele A, Demetri GD (2005) Gastrointestinal Stromal Tumor: New Nodule-within-a-Mass Pattern of Recurrence after Partial Response to Imatinib Mesylate. Radiology 235:892\u2013898","journal-title":"Radiology"},{"key":"4875_CR27","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/1471-2407-9-208","volume":"9","author":"M Horger","year":"2009","unstructured":"Horger M, Lauer UM, Schraml C, Berg CP, Koppenh\u00f6fer U, Claussen CD, Gregor M, Bitzer M (2009) Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib. BMC Cancer 9:208","journal-title":"BMC Cancer"},{"key":"4875_CR28","doi-asserted-by":"publisher","first-page":"281","DOI":"10.2214\/AJR.09.4110","volume":"195","author":"M Nishino","year":"2010","unstructured":"Nishino M, Jagannathan JP, Ramaiya NH, Van den Abbeele AD (2010) Revised RECIST Guideline Version 1.1: What Oncologists Want to Know and What Radiologists Need to Know. American Journal of Roentgenology 195:281\u2013289","journal-title":"American Journal of Roentgenology"},{"key":"4875_CR29","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1148\/rg.e38","volume":"30","author":"L Curvo-Semedo","year":"2010","unstructured":"Curvo-Semedo L, Brito JB, Seco MF, Costa JF, Marques CB, Caseiro-Alves F (2010) The Hypointense Liver Lesion on T2-Weighted MR Images and What It Means. RadioGraphics 30:e38","journal-title":"RadioGraphics"},{"key":"4875_CR30","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13027-022-00429-z","volume":"17","author":"V Granata","year":"2022","unstructured":"Granata V, Fusco R, Belli A, et al (2022) Conventional, functional and radiomics assessment for intrahepatic cholangiocarcinoma. Infect Agent Cancer 17:13","journal-title":"Infect Agent Cancer"},{"key":"4875_CR31","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1159\/000453009","volume":"32","author":"S-C Olthof","year":"2016","unstructured":"Olthof S-C, Othman A, Clasen S, Schraml C, Nikolaou K, Bongers M (2016) Imaging of Cholangiocarcinoma. Visc Med 32:402\u2013410","journal-title":"Visc Med"},{"key":"4875_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1433480","author":"B Kalaghchi","year":"2024","unstructured":"Kalaghchi B, Ince S, Barnes J, et al (2024) Arterial hypoperfusion as a negative predictive marker for primary hepatic malignancies treated with Y-90 glass microsphere transarterial radioembolization. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2024.1433480","journal-title":"Front Oncol"},{"key":"4875_CR33","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1007\/s00259-021-05600-z","volume":"49","author":"M Weber","year":"2022","unstructured":"Weber M, Lam M, Chiesa C, et al (2022) EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging 49:1682\u20131699","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4875_CR34","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1148\/radiol.14132362","volume":"273","author":"J-Y Choi","year":"2014","unstructured":"Choi J-Y, Lee J-M, Sirlin CB (2014) CT and MR Imaging Diagnosis and Staging of Hepatocellular Carcinoma: Part II. Extracellular Agents, Hepatobiliary Agents, and Ancillary Imaging Features. Radiology 273:30\u201350","journal-title":"Radiology"},{"key":"4875_CR35","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1097\/RLI.0b013e31829810f7","volume":"48","author":"F Morsbach","year":"2013","unstructured":"Morsbach F, Pfammatter T, Reiner CS, et al (2013) Computed Tomographic Perfusion Imaging for the Prediction of Response and Survival to Transarterial Radioembolization of Liver Metastases. Invest Radiol 48:787\u2013794","journal-title":"Invest Radiol"},{"key":"4875_CR36","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1055\/s-0043-1764310","volume":"06","author":"S Sen","year":"2023","unstructured":"Sen S, Gehani A, Ghosh P, Patra A, Mukhopadhyay S, Chandra A, Lingegowda D, Khoda J, Chatterjee A (2023) Pathological Basis of Imaging in Hepatocellular Carcinoma. Journal of Gastrointestinal and Abdominal Radiology 06:160\u2013172","journal-title":"Journal of Gastrointestinal and Abdominal Radiology"},{"key":"4875_CR37","first-page":"1547","volume":"60","author":"H Okubo","year":"2013","unstructured":"Okubo H, Mogami M, Ozaki Y, Igusa Y, Aoyama T, Amano M, Kokubu S, Miyazaki A, Watanabe S (2013) Liver function test by gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging with consideration of intrahepatic regional differences. Hepatogastroenterology 60:1547\u201351","journal-title":"Hepatogastroenterology"},{"key":"4875_CR38","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s43055-021-00601-2","volume":"52","author":"A Elsahhar","year":"2021","unstructured":"Elsahhar A, Abdelwahab SM, Nasser HM, Hassan MS (2021) Assessment of the relationship between hepatocellular carcinoma location and its response to transarterial chemoembolization. Egyptian Journal of Radiology and Nuclear Medicine 52:220","journal-title":"Egyptian Journal of Radiology and Nuclear Medicine"},{"key":"4875_CR39","doi-asserted-by":"publisher","first-page":"6437","DOI":"10.3748\/wjg.v23.i35.6437","volume":"23","author":"I Miki","year":"2017","unstructured":"Miki I, Murata S, Uchiyama F, et al (2017) Evaluation of the relationship between hepatocellular carcinoma location and transarterial chemoembolization efficacy. World J Gastroenterol 23:6437\u20136447","journal-title":"World J Gastroenterol"}],"container-title":["Abdominal Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00261-025-04875-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00261-025-04875-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00261-025-04875-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T07:47:12Z","timestamp":1757144832000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00261-025-04875-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,17]]},"references-count":39,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["4875"],"URL":"https:\/\/doi.org\/10.1007\/s00261-025-04875-2","relation":{},"ISSN":["2366-0058"],"issn-type":[{"type":"electronic","value":"2366-0058"}],"subject":[],"published":{"date-parts":[[2025,3,17]]},"assertion":[{"value":"26 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}